Biotech ETF SBIO Laps Tech Rivals Over 1 Year
If there were a defining sector for investors this year, it has been tech investing. The ascendance of AI has lifted valuations and investor portfolios, boosting the market as a whole.
Tailwinds Emerging for This Biotech ETF
The effects of the Federal Reserve's recent interest rate cut haven't fully been felt by the economy or financial markets. But the first instance of U.S. monetary easing in over four years may be a boon for capital-intensive biotech companies.
Biotech Stocks Are Perking Up. This ETF Is Responding
In a somewhat quiet fashion, long-lagging biotech stocks and exchange traded funds are perking up. The ALPS Medical Breakthroughs ETF (SBIO) is part of that group.
Biotech ETF SBIO Rides Strong Momentum into Rate Cuts
While many investors are on the lookout for ETF opportunities in rate cuts, one particular strategy is already standing out. The biotech ETF SBIO is riding some positive momentum thanks to some major changes in the space this year.
Positive Biotech M&A Activity in 1H Boosts Case for Biotech ETF SBIO
Following some notable uncertainty in recent years, M&A activity looks to be in recovery. In the first half of this year, biotech M&A activity saw some positive numbers, per a new J.P.
Returns Spiking for This Rate-Sensitive ETF
On the lookout for an ETF that might respond particularly well to rate cuts? One rate-sensitive ETF to watch is seeing returns spike even before rate cuts arrive.
Patent Cliffs Could Spark Wave of Biotech M&A
There's long been talk of a new wave of biotech mergers and acquisitions activity coming to life. In modest amounts, there has been evidence of that playing out.
Big Pharma Has the Firepower for Biotech Deal-Making
In the early innings of 2024, there was a flurry of consolidation in the biotech industry. It stoked hopes that this would finally be the year in which well-heeled blue-chip pharmaceutical companies would spend some of their cash on faster-growing biotech firms.
